Summer 2026
Hardware Intern
Posted on 2/26/2026
Culture Biosciences
51-200 employees
Remote bioprocessing services via bioreactor platform
Compensation Overview
$35 - $40/hr
San Bruno, CA, USA
In Person
 Hardware Engineering (1) |
|---|
- You are between your junior and senior years in a university or college.
- Currently pursuing a Bachelor of Science in Mechanical Engineering or similar.
- Knowledge of mechanical engineering design principles and computer-aided design software, with Onshape being a plus.
- Good verbal and written communication skills.
- Some familiarization with machining, sheet metal, and 3D printing.
- Some project experience in making parts.
- Assist in design of mechanical components and systems.
- Work closely with senior engineers and scientists in research and experimentation.
- Support testing and validation activities.
- Collaborate in cross functional teams across disciplines.
- Learn about fermentation, cell culture, and biotechnology.
- Familiarity with other 3D computer-aided design tools such as Solidworks, PTC, or NX.
- Basic skills and interest in prototyping and fabrication.
- Data analysis and writing technical reports.
Culture Biosciences provides a service-based platform for large-scale biomanufacturing. It designs, monitors, and analyzes high-throughput bioprocessing experiments for client projects using an integrated bioreactor system that can be operated remotely, enabling customers to run cells under controlled conditions at scale. The company’s product works by offering end-to-end bioprocess services: experiment design, real-time monitoring, data analysis, and technical transfer, all executed on Culture’s bioreactor platform. This combination differentiates Culture Biosciences from competitors by delivering scalable bioprocessing capabilities as a service with remote operation and a focus on scale-down-to-scale-up transfers, rather than selling equipment alone. The company’s goal is to help biotechnology clients efficiently explore and optimize manufacturing processes to enable faster, more predictable scale-up to commercial production.
Company Size
51-200
Company Stage
Series B
Total Funding
$101.7M
Headquarters
San Francisco, California
Founded
2016
Simplify's Take
What believers are saying
- Series C funding from Northpond Ventures accelerates Stratyx 250 commercialization.
- Mike Stapleton's 30-year expertise drives hardware and SaaS market expansion.
- Partnerships with Xcell Biosciences and Google Cloud boost AI capabilities.
What critics are saying
- CEO turnover from Darcy Birse to Chris Williams signals leadership instability.
- Stratyx 250 lacks customer wins post-Series C in December 2025.
- Hardware pivot strains resources amid competition from Cytiva and Lonza.
What makes Culture Biosciences unique
- Stratyx 250 delivers mobile, cloud-connected bioreactors for automated bioprocessing.
- Console SaaS integrates AI for predictive modeling and real-time data analysis.
- Nexxys service enables remote high-throughput bioprocessing experiments.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Culture Biosciences who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
Parental Leave
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 5%2 year growth
↑ 2%Firm advises Culture Biosciences on Series C financing round. On December 16, 2025, Culture Biosciences, a leader in cloud-based biomanufacturing, announced the successful close of its Series C fundraising round led by existing investors including Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox, reflecting strong conviction among current shareholders in Culture's trajectory and long-term strategy. Wilson Sonsini Goodrich & Rosati advised Culture on the transaction. The Series C financing will accelerate the commercial expansion of Culture's next-generation hardware product, the Stratyx 250, as well as fuel continued development of the company's AI-powered Console software ecosystem. The Stratyx 250 system is engineered to provide scalable, automated, and digitally connected bioprocess capacity designed for modern biologics, cell therapy, and advanced bioprocess development needs. In parallel, Culture will expand the AI-enabled capabilities of its Console software platform, including advanced data integration, predictive modeling, and automated analysis tools intended to streamline development cycles and enhance process decision-making for customers. The Wilson Sonsini team that advised Culture on the financing included Andrew Hoffman, Terence Desouza, Utsav Lall, Kate Kirkpatrick, Michael Murrietta, and Casey Hepburn. For more information, please see Culture's news release.
Culture Biosciences announces close of Series C round to accelerate commercial growth of Stratyx 250 and Console platform. New funding accelerates the expansion of the Stratyx(TM) platform, advancing automated, cloud-connected bioprocessing and AI-driven software capabilities SOUTH SAN FRANCISCO, CALIFORNIA, UNITED STATES, Dec. 16, 2025 (GLOBE NEWSWIRE) - South San Francisco, CA - December 16, 2025 - Culture Biosciences ("Culture"), a leader in cloud-based biomanufacturing, today announced the successful close of its Series C fundraising round led by existing investors including Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox, reflecting strong conviction among current shareholders in Culture's trajectory and long-term strategy. The Series C financing will accelerate the commercial expansion of Culture's next-generation hardware product, the Stratyx 250, as well as fuel continued development of the company's AI-powered Console software ecosystem. The Stratyx 250 system is engineered to provide scalable, automated, and digitally connected bioprocess capacity designed for modern biologics, cell therapy, and advanced bioprocess development needs. In parallel, Culture will expand the AI-enabled capabilities of its Console software platform, including advanced data integration, predictive modeling, and automated analysis tools intended to streamline development cycles and enhance process decision-making for customers. This follows Culture's previous announcements regarding collaborations with both Google Cloud and Cytiva's Scaler Tool. "This round reflects the confidence our existing investors have in Culture's technology and long-term roadmap," said Chris Williams, CEO of Culture Biosciences. "With the Stratyx 250 platform, we're delivering the next major leap in automated bioprocessing infrastructure. This new capital allows us to scale production, advance our Console software ecosystem, and continue helping customers bring therapies to market faster." "We believe Culture is setting a new standard for digitally integrated bioprocessing," said Andrew Lee, Managing Director at Northpond Ventures. "The Stratyx 250 system and Culture's expanding software capabilities represent transformative tools for the future of biomanufacturing and AI, and we are excited to continue supporting the team as they bring these capabilities to customers globally." "Biopharma and synthetic biology companies increasingly need infrastructure that can unify high-throughput experimentation with intelligent, data-driven process design," said Shivani Oberoi, Principal at Synthesis Capital. "Culture's core technology remains exceptionally well aligned with those needs, and we are pleased to continue backing the company as it scales and accelerates the next phase of its commercial expansion." About Culture Biosciences Culture is on a mission to revolutionize bioprocess development with a powerful combination of hardware and cloud-native software-that makes data accessible, contextualized, and actionable-unlocking the full potential of end-to-end bioprocessing capabilities. For Culture Biosciences
Culture Biosciences, a South San Francisco-based cloud biomanufacturing company, has closed its Series C funding round led by existing investors including Northpond Ventures, Synthesis Capital, S32 and Cultivian Sandbox. The funding amount was not disclosed. The capital will accelerate commercial expansion of Culture's Stratyx 250 system, an automated bioprocessing platform for biologics and cell therapy development, and advance its AI-powered Console software ecosystem. The software includes predictive modelling and automated analysis tools designed to streamline development cycles. Culture has previously announced collaborations with Google Cloud and Cytiva's Scaler Tool. The company develops cloud-based biomanufacturing infrastructure combining hardware and software to enhance bioprocess development and data integration for pharmaceutical and synthetic biology companies.
Culture Biosciences has introduced a new solution for biotech and cellular agriculture teams: the Stratyx 250, a mobile, cloud-based bioreactor system designed to streamline process development. This new bioreactor promises to cut down on development time and costs, improve scalability, and simplify bioprocess monitoring and control, offering key benefits for growing companies in the cellular agriculture space.The Stratyx 250 is tailored to meet the specific needs of biotech companies, particularly those working on cellular agriculture, where efficient scaling and optimization are critical. Traditionally, bioreactor systems require extensive manual oversight, specialized expertise, and complex infrastructure to process vast amounts of experimental data. The Stratyx 250 addresses these challenges by combining automation, AI-driven data analysis, and cloud-based control, enabling remote monitoring and real-time adjustments. This means that teams can make data-driven decisions faster and more efficiently, improving the consistency and reproducibility of experiments.© Culture Biosciences. Efficiency and scalabilityOne of the standout features of the Stratyx 250 is its mobility
Culture Biosciences has introduced the Stratyx 250, a mobile bioreactor system designed to streamline biotech and cellular agriculture process development.